Gossamer Bio (NASDAQ: GOSS) saw its shares jump 46.6% on Monday, reaching $0.1994, after the FDA provided feedback that supports the company's planned submission of seralutinib in September. The rally continued in premarket trading, with shares changing hands at around $0.2613, roughly 31% higher than Monday's close.
The FDA indicated that concerns regarding the statistical significance and treatment effect of the PROSERA study are matters for review, not for the initial filing. This distinction is crucial as it allows Gossamer to proceed with its New Drug Application (NDA) without awaiting additional data. If accepted, a decision could come in the third quarter of 2027.
While this news reduces near-term regulatory uncertainty, it does not guarantee approval. The FDA will evaluate the full application before making a final decision on approvability. The company's near-term focus remains on the submission and the potential need for additional financing.
Financing has become a more prominent concern for investors. As of June 30, Gossamer's preliminary cash, cash equivalents, and securities stood at approximately $57 million. The company's secured notes require a minimum liquidity of $40 million, tested monthly, providing a basic buffer of $17 million. A $5 million payment due from Chiesi would increase this buffer to $22 million, not accounting for new expenses. In the first quarter, the company consumed $38.7 million in cash from operations, meaning the pro forma buffer represents about 57% of that quarterly burn rate.
The covenant structure includes an equity provision. The minimum liquidity requirement drops to $20 million once Gossamer raises at least $100 million in equity proceeds. If the FDA accepts the filing by December 1, the floor may drop further to $10 million. Should cumulative equity proceeds reach $150 million, the floor can be eliminated entirely.
The June debt swap significantly altered the company's capital structure. Gossamer issued 254.2 million common shares and 33.4 million prefunded warrants. Additionally, it granted 135.8 million purchase warrants and $65.2 million in new convertible notes. If fully converted at the initial rate, the notes would represent approximately 348.5 million shares, with a conversion price of about $0.19—close to Monday's closing price. There is no guarantee that noteholders will convert or exercise warrants, but the potential dilution is substantial.
The updated deal with Chiesi gives Gossamer a larger share of sales economics. The previous 50/50 profit split for the U.S. ends, and rights outside the U.S. revert to Gossamer. Royalty and milestone payments remain capped, and Gossamer will no longer share development costs. Chief Executive Faheem Hasnain described the update as "a defining moment for Gossamer."
Analysts have responded positively. Leerink raised its rating to Outperform, maintaining a $1 price target. H.C. Wainwright reaffirmed its Buy rating and $2 target. The stock had plummeted 80% in February after PROSERA missed its primary endpoint, showing a 13.3-meter improvement in placebo-adjusted walking distance over 24 weeks but failing to achieve statistical significance. The stock had declined 20% over the prior week, hitting $0.136 by July 24, before Monday's rally recouped those losses and more.
Looking ahead, Gossamer's public calendar shows no scheduled events. Market focus in the coming week will be on continued momentum and any financing announcements. Risks remain concentrated: the FDA may reject the submission or withhold approval, accessing fresh capital could be expensive or unavailable, and the company states its prospects rest solely on seralutinib. A reverse stock split is anticipated in or shortly after the third quarter.
